Literature DB >> 3514760

Substrate specificity and partial characterization of the PAF-acylhydrolase in human serum that rapidly inactivates platelet-activating factor.

M L Wardlow, C P Cox, K E Meng, D E Greene, R S Farr.   

Abstract

The structure of the potent inflammatory mediator, platelet-activating factor, is 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (AGEPC, PAF-acether). Human sera contain an acid labile factor (ALF) that is a Ca+2-independent 2-acylhydrolase-specific for AGEPC and AGEPC-like molecules. The enzyme functions by catalytically removing the sn-2 acetyl moiety from AGEPC, producing the biologically inactive sn-2 hydroxy form or 2-lyso-GEPC. Incubation of ALF with sn-2 acyl PAF analogs indicated that the enzyme hydrolyzes the sn-2 fatty acid only if the chain length is five carbons or less, the sn-1 position fatty acid length is greater than 10 carbon units, and at least one methyl group is present on the terminal amine of the choline group. The enzyme was active with either an ether or ester linkage at the sn-1 position. ALF is inactivated by heating to 65 degrees C for 30 min. It is pronase and trypsin sensitive but resistant to papain and papain with dithiothreitol. Further characteristics of human ALF indicated a broad pH range of activity with an optimum of pH 6.2 and an isoelectric point of 6.2 to 6.7. The specificity and Ca+2 independence of human ALF sets it apart from phospholipase A2. It is proposed that human ALF be called human serum PAF-acylhydrolase to distinguish it from other hydrolases currently known to exist.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3514760

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  13 in total

Review 1.  Excitable membranes, lipid messengers, and immediate-early genes. Alteration of signal transduction in neuromodulation and neurotrauma.

Authors:  J P Doucet; N G Bazan
Journal:  Mol Neurobiol       Date:  1992       Impact factor: 5.590

2.  Radioimmunoassay for platelet-activating factor.

Authors:  K Karasawa; N Satoh; T Hongo; Y Nakagawa; M Setaka; S Nojima
Journal:  Lipids       Date:  1991-12       Impact factor: 1.880

3.  Platelet-activating-factor-mediated pathogenesis in Lyme disease.

Authors:  E Isogai; K Kimura; N Fujii; T Nishikawa; N Ishii; D Postic; G Baranton; H Isogai
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

4.  Characterization of a platelet-activating factor acetylhydrolase secreted by the nematode parasite Nippostrongylus brasiliensis.

Authors:  M E Grigg; K Gounaris; M E Selkirk
Journal:  Biochem J       Date:  1996-07-15       Impact factor: 3.857

Review 5.  Lipoprotein-associated phospholipase A2: The story continues.

Authors:  Fubao Huang; Kai Wang; Jianhua Shen
Journal:  Med Res Rev       Date:  2019-05-29       Impact factor: 12.944

Review 6.  Platelet-activating factor: the biosynthetic and catabolic enzymes.

Authors:  F Snyder
Journal:  Biochem J       Date:  1995-02-01       Impact factor: 3.857

7.  Oxygen radicals inhibit human plasma acetylhydrolase, the enzyme that catabolizes platelet-activating factor.

Authors:  G Ambrosio; A Oriente; C Napoli; G Palumbo; P Chiariello; G Marone; M Condorelli; M Chiariello; M Triggiani
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

8.  Factors that influence the proportions of platelet-activating factor and 1-acyl-2-acetyl-sn-glycero-3-phosphocholine synthesized by the mast cell.

Authors:  M Triggiani; A N Fonteh; F H Chilton
Journal:  Biochem J       Date:  1992-09-01       Impact factor: 3.857

9.  Lipoproteins alter the catalytic behavior of the platelet-activating factor acetylhydrolase in human plasma.

Authors:  D M Stafforini; M E Carter; G A Zimmerman; T M McIntyre; S M Prescott
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

10.  Platelet-activating factor acetylhydrolase activity in maternal, fetal, and newborn rabbit plasma during pregnancy and lactation.

Authors:  N Maki; D R Hoffman; J M Johnston
Journal:  Proc Natl Acad Sci U S A       Date:  1988-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.